Hepatocellular carcinoma patients with performance status 1 deserve new classification and treatment algorithm in the bclc system

Medicine (United States)

Volumn 94, Issue 29, 2015, Pages

  Hsu, Chia Yang ^a   Liu, Po Hong ^b   Lee, Yun Hsuan ^a   Hsia, Cheng Yuan ^a   Huang, Yi Hsiang ^c   Chiou, Yi You ^a   Lin, Han Chieh ^d,e   Huo, Teh Ia ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b Department of Surgery ^*  (Taiwan)

^c Faculty of Medicine   (Taiwan)

^d Institute of Clinical Medicine   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; BILIRUBIN;

ABLATION THERAPY; ADULT; AGE; AGED; ALGORITHM; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; ASCITES; BARCELONA CLINIC LIVER CANCER SYSTEM; BILIRUBIN BLOOD LEVEL; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CHEMOEMBOLIZATION; CHRONIC LIVER DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HUMAN; HYPOALBUMINEMIA; KIDNEY FUNCTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER RESECTION; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PATIENT CARE; PERCUTANEOUS RADIOFREQUENCY ABLATION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; RADIOFREQUENCY ABLATION; SCORING SYSTEM; SEX DIFFERENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; CARCINOMA, HEPATOCELLULAR; CLASSIFICATION; CLINICAL PROTOCOL; HEALTH STATUS INDICATOR; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; LIVER NEOPLASMS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; SURVIVAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALGORITHMS; CARCINOMA, HEPATOCELLULAR; CLINICAL PROTOCOLS; FEMALE; HEALTH STATUS INDICATORS; HUMANS; KIDNEY FUNCTION TESTS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84942436330     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001223     Document Type: Article

References (24)

1. El-Serag HB, Marrero JA, Rudolph L, et al. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752-1763
2. Li L, Zhang J, Liu X, et al. Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-Analysis. J Gastroenterol Hepatol. 2012;27:51-58
3. Chan SL, Yeo W. Targeted therapy of hepatocellular carcinom: present and future. J Gastroenterol Hepatol. 2012;27:862-872
4. Chaparro M, Gonzalez Moreno L, Trapero-Marugan M, et al. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. Aliment Pharmacol Ther. 2008;28:1269-1277
5. Llovet JM, Ducreux M, Lencioni R, et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943
6. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022
7. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655
8. Hsu CY, Lee YH, Liu PH, et al. Decrypting cryptogenic hepatocellular carcinoma: clinical manifestations, prognostic factors and longterm survival by propensity score model. PLoS One. 2014;9:e89373
9. Lee YH, Hsu CY, Hsia CY, et al. Defining the severity of liver dysfunction in patients with hepatocellular carcinoma by the model for end-stage liver disease-derived systems. Dig Liver Dis. 2012;44:868-874
10. Hsu CY, Liu PH, Lee YH, et al. Active treatments prolong the survival in patients with hepatocellular carcinoma and performance status 3 or 4: a propensity score analysis. J Clin Gastroenterol. 2015(in press)
11. Hsu CY, Liu PH, Lee YH, et al. Using serum a-fetoprotein for prognostic prediction in patients with hepatocellular carcinoma: what is the most optimal cutoff? PLoS One. 2015;10:e0118825
12. Hsu CY, Lee YH, Hsia CY, et al. Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. Hepatology. 2013;57:112-119
13. Hsu CY, Huang YH, Hsia CY, et al. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol. 2010;53:108-117
14. Austin PC, Schuster T. The performance of different propensity score methods for estimating absolute effects of treatments on survival outcomes: a simulation study. Stat Methods Med Res. 2015(in press).
15. Austin PC. A comparison of 12 algorithms for matching on the propensity score. Stat Med. 2014;33:1057-1069
16. Hsu CY, Lee YH, Hsia CY, et al. Performance status enhances the selection of treatment for patients with hepatocellular carcinoma within the milan criteria. Ann Surg Oncol. 2013;20:2035-2042
17. Gomaa AI, Hashim MS, Waked I. Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in egypt. PLoS One. 2014;9:e90929
18. Kim BK, Kim SU, Park JY, et al. Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naive patients with hepatocellular carcinoma. Liver Int. 2012;32:1120-1127
19. Yau T, Tang VY, Yao TJ, et al. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014;146:1691-1700
20. Kudo M, Osaki Y, Matsunaga T, et al. Hepatocellular carcinoma in Child-Pugh C cirrhosis: prognostic factors and survival benefit of nontransplant treatments. Dig Dis. 2013;31:490-498
21. Ruzzenente A, Capra F, Pachera S, et al. Is liver resection justified in advanced hepatocellular carcinoma? Results of an observational study in 464 patients. J Gastrointest Surg. 2009;13:1313-1320
22. Tokushige K, Hashimoto E, Yatsuji S, et al. Prospective study of hepatocellular carcinoma in nonalcoholic steatohmepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. J Gastroenterol. 2010;45:960-967
23. Kew MC, Geddes EW. Hepatocellular carcinoma in rural southern African blacks. Medicine. 1982;61:98-108
24. Lee IC, Chen YT, Chao Y, et al. Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice. Medicine. 2015;94:e688